Allergan, FDA fight eyelash-mad copycats

It looks like a drug, it acts like a drug, but if comes in a cosmetics tube instead of an eyedropper, is it still a drug?

Call it the case of the thicker-lashed glaucoma patient. Lumigan, a glaucoma remedy sold by Allergan, has the unusual added benefit of promoting eyelash growth. Some eye docs are prescribing it not only to glaucoma patients, but off-label for cosmetics use. Meanwhile, an entrepreneurial cosmetics maker allegedly used similar ingredients in a mascara-like package. The FDA seized raided the company and seized boxes of the product on Friday, calling it a "mislabeled drug."

Meanwhile, Allergan itself is rumored to be testing Lumigan for cosmetic use. And it has sued seven cosmetics companies for patent infringement. Of course, the company has plenty of experience pushing medical remedies into the profitable cosmeceuticals realm. Remember Botox?

- check out the Wall Street Journal article

Related Articles:
Allergan wins FDA OK for new therapy. Report
Allergan injects $370M into Esprit buyout. Report
Allergan buying Groupe Corneal. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.